ReviewClinical ophthalmology (Auckland, N.Z.)2022
Glaucoma and Ocular Surface Disease: More than Meets the Eye.
Review in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- iStent combined with phacoemulsification versus phacoemulsification alone in open-angle glaucoma: a meta-analysis by medication washout status.BMC ophthalmology · 2026Pooled it
- Association between the use of prostaglandin analogues and ocular surface disease: a systematic review.Eye (London, England) · 2025Pooled it
- Comparison of postoperative cyclosporine 2.0% versus betamethasone 0.1% eye drops following trabeculectomy: A randomized clinical trial.Indian journal of ophthalmology · 2025Trial
- Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Ocular Surface Symptoms, Objective Redness, and Intraocular Pressure After a Switch from Fixed Dorzolamide/Timolol to Netarsudil in Latanoprost-Treated Glaucoma and Ocular Hypertension: A Prospective Real-World Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- 5-year outcomes of iStent micro-bypass vs. Kahook dual blade goniotomy in open angle glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Ocular Surface Inflammation as a Driver of Cornea Limbal Stem Cell Deficiency: Mechanisms and Implications.International journal of molecular sciences · 2026Review
- Effects of Trehalose, Sodium Hyaluronate and N-Acetyl Aspartyl-Glutamic Acid Artificial Tears on Ocular Surface Parameters in Glaucoma Patients Receiving Preserved and Preservative-Free Prostaglandins.Journal of clinical medicine · 2026Article
- Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension.Ophthalmology and therapy · 2026Article
- Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Limbal stem cell deficiency secondary to topical glaucoma medication: a scoping review.International journal of ophthalmology · 2026Review
- A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFYOphthalmology and therapy · 2025Article
- TUT7-Mediated Uridine Degradation of MCPIP1 in the Pterygium to Regulate TRAF6-Mediated Autophagy.Investigative ophthalmology & visual science · 2025Article
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.Bioengineering (Basel, Switzerland) · 2024Review
- FAST® questionnaire for identifying glaucoma patients at risk for ocular surface disease.European journal of ophthalmology · 2024Article
- Article
- Use Pattern of Ophthalmic Antiglaucoma Agents with and without Preservatives: A Cross-Sectional Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- [Diagnostics of ocular mucous membrane pemphigoid].Die Ophthalmologie · 2023Review
- Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024.Journal of current glaucoma practiceArticle
- A Retrospective Cohort Study Analyzing Postoperative Safety and Efficacy of a Baerveldt Glaucoma Implant Modification for Earlier Intraocular Pressure Lowering, Compared to Nonmodified Baerveldt Implants at 3 Months.Journal of current glaucoma practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the association between ocular surface disease and glaucoma is important for improving adherence to treatment and introducing practical solutions. While topical antihypertensive medications for glaucoma are well tolerated according to short-term studies, there is little evidence on their long-term effects. Since they are often required for many years, the effects of these drops on the ocular surface become important in regard to quality of life and adherence. In this nonsystematic review performed in April 2022, we summarize what is known about the relationship between glaucoma and ocular surface disease. Specifically, we examine how each class of topical glaucoma drops affects the ocular surface. We then review the treatment of ocular surface disease for patients on topical glaucoma therapy. Finally, we discuss treatments that may reduce or eliminate the burden of topical medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.